For assessment of therapeutic efficacy, mice bearing subcutaneous PC3‐PIP xenografts were administered I.V. once 4.63 kBq in total that was delivered either by the PSMA‐targeting antibody alone, or by the tumor‐responsive liposomes alone, and/or by different radioactivity split ratios between the two carriers injected simultaneously, in addition to the cold liposomes and the cold antibody. The gene discussed is FOLH1; the disease is neoplasm.